Ekso Bionics Holdings (Nasdaq:EKSO) - Cotización, noticias y análisis

Resumen de acción EKSO

Ekso Bionics Holdings, Inc. diseña, desarrolla, vende y alquila productos de exoesqueleto en América, Alemania, Polonia, Europa, Oriente Medio, África, Asia-Pacífico e internacionalmente.

Acerca de la empresa

EKSO fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 23.82%

Análisis de riesgos

Los accionistas han sido diluidos en el último año

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

No tiene una capitalización de mercado significativa ($19M)

Volatilidad del precio de la acción en los últimos 3 meses

Competidores de Ekso Bionics Holdings, Inc.

Precision Optics Corporation

NasdaqCM:POCI

US$33.4m

SANUWAVE Health

OTCPK:SNWV

US$27.1m

STRATA Skin Sciences

NasdaqCM:SSKN

US$19.1m

Cue Health

NasdaqCM:HLTH

US$23.0m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Ekso Bionics Holdings
Historical stock prices
Current Share Price	US$1.32
52 Week High	US$3.13
52 Week Low	US$0.62
Beta	1.64
1 Month Change	-8.33%
3 Month Change	-37.14%
1 Year Change	-20.48%
3 Year Change	-76.84%
5 Year Change	-95.91%
Change since IPO	-99.47%

Noticias y actualizaciones recientes

Recent updates

Market Still Lacking Some Conviction On Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Dec 20

Shareholders May Not Be So Generous With Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) CEO Compensation And Here's Why

Jun 04

Is Ekso Bionics Holdings (NASDAQ:EKSO) Weighed On By Its Debt Load?

May 26

What Is The Ownership Structure Like For Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)?

Feb 10

Ekso Bionics sees lower 2020 sales vs. 2019

Jan 13

Health Check: How Prudently Does Ekso Bionics Holdings (NASDAQ:EKSO) Use Debt?

Dec 23

Ekso Bionics Holdings EPS beats by $0.38, beats on revenue

Oct 29

Rentabilidad de los accionistas

	EKSO	US Medical Equipment	Mercado US
7D	-5.7%	-2.9%	-3.2%
1Y	-20.5%	-3.7%	19.3%

Rentabilidad vs. Industria: EKSO obtuvo unos resultados inferiores a los del sector US Medical Equipment , que el año pasado arrojó un rendimiento del 14.2%.

Rentabilidad vs. Mercado: EKSO obtuvo unos resultados inferiores a los del mercado US, que fue del 26.2% el año pasado.

Volatilidad de los precios

Is EKSO's price volatile compared to industry and market?
EKSO volatility
EKSO Average Weekly Movement	14.7%
Medical Equipment Industry Average Movement	7.4%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: EKSOha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: EKSO(20%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2005	71	Scott Davis	www.eksobionics.com

Ekso Bionics Holdings, Inc. diseña, desarrolla, vende y alquila productos de exoesqueleto en América, Alemania, Polonia, Europa, Oriente Medio, África, Asia-Pacífico e internacionalmente. Opera en dos segmentos, EksoHealth y EksoWorks. El segmento EksoHealth diseña, fabrica y comercializa exoesqueletos para aplicaciones en los mercados médicos.

Resumen de fundamentos de Ekso Bionics Holdings, Inc.

¿Cómo se comparan los beneficios e ingresos de Ekso Bionics Holdings con su capitalización de mercado?
Estadísticas fundamentales de EKSO
Capitalización bursátil	US$23.63m
Beneficios(TTM)	-US$15.20m
Ingresos (TTM)	US$18.28m

1.3x

Ratio precio-ventas (PS)

-1.6x

Ratio precio-beneficio (PE)

¿Está EKSO sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de EKSO
Ingresos	US$18.28m
Coste de los ingresos	US$9.20m
Beneficio bruto	US$9.08m
Otros gastos	US$24.28m
Beneficios	-US$15.20m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.85
Margen bruto	49.67%
Margen de beneficio neto	-83.14%
Ratio deuda/patrimonio	48.2%

¿Cómo se ha desempeñado EKSO a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción EKSO

Recompensas

Análisis de riesgos

Competidores de Ekso Bionics Holdings, Inc.

NasdaqCM:POCI

US$33.4m

OTCPK:SNWV

US$27.1m

NasdaqCM:SSKN

US$19.1m

NasdaqCM:HLTH

US$23.0m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Consensus EPS estimates fall by 145%

Price target decreased by 7.5% to US$9.25

No longer forecast to breakeven

Full year 2023 earnings: EPS misses analyst expectations

Ekso Bionics Holdings, Inc. to Report Q4, 2023 Results on Mar 04, 2024

Consensus estimates of losses per share improve by 26%

Recent updates

Consensus EPS estimates fall by 145%

Price target decreased by 7.5% to US$9.25

No longer forecast to breakeven

Full year 2023 earnings: EPS misses analyst expectations

Ekso Bionics Holdings, Inc. to Report Q4, 2023 Results on Mar 04, 2024

Consensus estimates of losses per share improve by 26%

Forecast to breakeven in 2026

Ekso Bionics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. Launches GaitCoach Software for EksoNR

Ekso Bionics Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023

Market Still Lacking Some Conviction On Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc. Receives CMS Coding Approval for Ekso Indego Personal

New major risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ekso Bionics Holdings, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Ekso Bionics Holdings, Inc. Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates increase by 12%, EPS downgraded

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ekso Bionics Holdings, Inc. to Report Q2, 2023 Results on Jul 27, 2023

New minor risk - Share price stability

Sentiment Still Eluding Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Executive Chairman of the Board recently sold US$66k worth of stock

Consensus EPS estimates fall by 40%

High number of new and inexperienced directors

No longer forecast to breakeven

Full year 2022 earnings released: US$1.16 loss per share (vs US$0.80 loss in FY 2021)

Forecast to breakeven in 2025

Ekso Bionics Holdings, Inc Announces Director Changes

Ekso Bionics Holdings, Inc. acquired Human Motion and Control Business Unit of Parker Hannifin Corporation for $10 million.

Price target decreased to US$9.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Ekso Bionics Holdings, Inc. Approves Appointment of Jerome Wong as Corporate Secretary and Principal Financial Officer

Ekso Bionics Holdings, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Ekso Bionics: Fragile Opportunity

Second quarter 2022 earnings: EPS exceeds analyst expectations

Ekso Bionics Holdings, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Is Ekso Bionics Holdings (NASDAQ:EKSO) A Risky Investment?

Ekso Bionics Holdings, Inc. Receives FDA Clearance to Market Its Eksonr(Tm) Robotic Exoskeleton for Use with Multiple Sclerosis Patients

Ekso Bionics Holdings, Inc. Announces Chief Financial Officer Changes

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 09, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$11.00

Ekso Bionics Holdings, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Ekso Bionics Holdings, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Health Check: How Prudently Does Ekso Bionics Holdings (NASDAQ:EKSO) Use Debt?

Ekso Bionics: Expecting More Of The Same

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.30 profit in 3Q 2020)

Is Ekso Bionics Holdings (NASDAQ:EKSO) Weighed On By Its Debt Load?

Second quarter 2021 earnings released: US$0.10 loss per share (vs US$1.88 loss in 2Q 2020)

Ekso Bionics: Have Robot, Might Travel

Shareholders May Not Be So Generous With Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) CEO Compensation And Here's Why

Is Ekso Bionics Holdings (NASDAQ:EKSO) Weighed On By Its Debt Load?

First quarter 2021 earnings released: US$0.34 loss per share (vs US$0.44 loss in 1Q 2020)

Director has left the company